UBS Group
IMRX icon

UBS Group’s Immuneering IMRX Stock Holding History

UBS Group’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.98M Buy
376,284
+185,951
+98% +$953K ﹤0.01% 4984
2025
Q4 		$1.25M Buy
190,333
+63,931
+51% +$410K ﹤0.01% 5390
2025
Q3 		$885K Buy
126,402
+121,329
+2,392% +$630K ﹤0.01% 5675
2025
Q2 		$17.1K Sell
5,073
-23,478
-82% -$40.2K ﹤0.01% 8544
2025
Q1 		$43.4K Sell
28,551
-23,942
-46% -$43.5K ﹤0.01% 7690
2024
Q4 		$115K Buy
52,493
+20,948
+66% +$43.4K ﹤0.01% 6782
2024
Q3 		$78.5K Buy
31,545
+24,492
+347% +$35.6K ﹤0.01% 6528
2024
Q2 		$9.03K Sell
7,053
-21,898
-76% -$36K ﹤0.01% 7765
2024
Q1 		$83.7K Buy
+28,951
New +$162K ﹤0.01% 6300
2023
Q2 		– Sell
-2,713
Closed -$26.3K – 9235
2023
Q1 		$26.3K Buy
+2,713
New +$15.4K ﹤0.01% 6882
2022
Q4 		– Sell
-105
Closed -$2K – 10912
2022
Q3 		$2K Sell
105
-1,296
-93% -$10.3K ﹤0.01% 9733
2022
Q2 		$8K Sell
1,401
-1,862
-57% -$9.93K ﹤0.01% 8312
2022
Q1 		$21K Buy
3,263
+1,643
+101% +$15.8K ﹤0.01% 7393
2021
Q4 		$26K Buy
1,620
+501
+45% +$12.2K ﹤0.01% 7539
2021
Q3 		$30K Buy
+1,119
New +$30.1K ﹤0.01% 6751

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group's IMRX Position: Q1 2026 in Review

UBS Group increased its Immuneering (IMRX) stake by 98% in Q1 2026, buying an estimated $953K and bringing the position to 376,284 shares worth $1.98M. The position accounts for ﹤0.01% of the portfolio, ranked #4984.

UBS Group first reported a position in IMRX in Q3 2021 and has held it in 15 quarters since. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • UBS Group held 376,284 shares of Immuneering worth $1.98M as of Q1 2026.
  • UBS Group bought 185,951 Immuneering shares in Q1 2026, an estimated $953K.
  • Immuneering made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4984 holding.
  • UBS Group first reported a position in Immuneering in Q3 2021 and has held it in 15 quarters since.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.